CytoMed Therapeutics Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. CytoMed Therapeutics Limited's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 20% to $290,560. The net income raised on -$3,131,788 and profit margin reached -1078%. Total operating expenses were $3,121,470.

Profit Margin

CytoMed Therapeutics Limited (NASDAQ:GDTC): Profit margin
2019 0 -850.76K
2020 44.92K -1.46M -3266.07%
2021 113.84K -2.07M -1822.31%
2022 363.91K -3.22M -887.02%
2023 290.56K -3.13M -1077.85%

GDTC Income Statement (2019 – 2023)

2023 2022 2021 2020 2019
Revenue
Revenue
290.56K363.91K113.84K44.92K0
Cost of revenue
77.46K8.72K3.50K3.49K0
Gross profit
213.09K355.19K110.33K41.42K0
Operating exp.
Research and development
1.20M1.52M1.09M784.19K591.54K
Selling and marketing
25.23K02.48K4.67K0
Total operating expenses
3.12M1.85M1.72M949.00K823.52K
Operating income
-2.91M-1.88M-1.93M-949.00K-815.88K
Other income (expenses), net
-219.50K-1.15M-209.39K-513.21K-34.87K
Income before tax
-3.13M-3.12M-2.07M-1.46M-850.76K
Income tax expense
3731.64K-72.25K84.70K0
Net income
-3.13M-3.22M-2.07M-1.46M-850.76K
Earnings per share
Basic EPS
-0.29-0.41-0.3-0.24-0.15
Diluted EPS
-0.29-0.41-0.3-0.24-0.15
Data sourceData source